Ruiz-Garcia Henry, Trifiletti Daniel M, Mohammed Nasser, Hung Yi-Chieh, Xu Zhiyuan, Chytka Tomas, Liscak Roman, Tripathi Manjul, Arsanious David, Cifarelli Christopher P, Caceres Marco Perez, Mathieu David, Speckter Herwin, Mehta Gautam U, Lekovic Gregory P, Sheehan Jason P
Department of Radiation Oncology, Mayo Clinic, Jacksonville, Florida, United States.
Department of Neurological Surgery, Mayo Clinic, Jacksonville, Florida, United States.
J Neurol Surg B Skull Base. 2021 Jan 19;83(Suppl 2):e173-e180. doi: 10.1055/s-0041-1722937. eCollection 2022 Jun.
Meningiomas are the second most common tumors in neurofibromatosis type 2 (NF-2). Microsurgery is challenging in NF-2 patients presenting with skull base meningiomas due to the intrinsic risks and need for multiple interventions over time. We analyzed treatment outcomes and complications after primary Gamma Knife radiosurgery (GKRS) to delineate its role in the management of these tumors. An international multicenter retrospective study approved by the International Radiosurgery Research Foundation was performed. NF-2 patients with at least one growing and/or symptomatic skull base meningioma and 6-month follow-up after primary GKRS were included. Clinical and radiosurgical parameters were recorded for analysis. In total, 22 NF-2 patients with 54 skull base meningiomas receiving GKRS as primary treatment met inclusion criteria. Median age at GKRS was 38 years (10-79 years). Most lesions were located in the posterior fossa (55.6%). Actuarial progression free survival (PFS) rates were 98.1% at 2 years and 90.0% at 5 and 10 years. The median follow-up time after initial GKRS was 5.0 years (0.6-25.5 years). Tumor volume at GKRS was a predictor of tumor control. Lesions >5.5 cc presented higher chances to progress after radiosurgery ( = 0.043). Three patients (13.64%) developed adverse radiation effects. No malignant transformation or death due to meningioma or radiosurgery was reported. GKRS is effective and safe in the management of skull base meningiomas in NF-2 patients. Tumor volume deserve greater relevance during clinical decision-making regarding the most appropriate time to treat. GKRS offers a minimally invasive approach of particular interest in this specific group of patients.
脑膜瘤是2型神经纤维瘤病(NF-2)中第二常见的肿瘤。由于存在内在风险且需要随着时间进行多次干预,对于患有颅底脑膜瘤的NF-2患者,显微手术具有挑战性。我们分析了初次伽玛刀放射外科治疗(GKRS)后的治疗效果和并发症,以明确其在这些肿瘤管理中的作用。
开展了一项经国际放射外科研究基金会批准的国际多中心回顾性研究。纳入至少有一个生长性和/或有症状的颅底脑膜瘤且初次GKRS后有6个月随访的NF-2患者。记录临床和放射外科参数以进行分析。
共有22例NF-2患者的54个颅底脑膜瘤接受了GKRS作为主要治疗,符合纳入标准。GKRS时的中位年龄为38岁(10 - 79岁)。大多数病变位于后颅窝(55.6%)。2年、5年和10年的无进展生存率分别为98.1%、90.0%。初次GKRS后的中位随访时间为5.0年(0.6 - 25.5年)。GKRS时的肿瘤体积是肿瘤控制的一个预测因素。体积>5.5 cc的病变在放射外科治疗后进展的可能性更高(P = 0.043)。3例患者(13.64%)出现了不良放射效应。未报告因脑膜瘤或放射外科治疗导致的恶变或死亡。
GKRS在NF-2患者颅底脑膜瘤的管理中是有效且安全的。在关于最合适治疗时间的临床决策过程中,肿瘤体积应得到更大的重视。GKRS为这一特定患者群体提供了一种特别有意义的微创方法。